이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

재발성 또는 진행성 고급 신경교종에서 DC 백신의 안전성 및 유효성 연구

2026년 9월 23일 업데이트: Yang Zhang, Beijing Tiantan Hospital

재발성 또는 진행성 고급 신경교종 치료를 위한 맞춤형 수지상 세포 주입 ZSNeo-DC1.1의 1상 임상시험

This is a single-center, open-label, multi-dose phase I clinical trial evaluating the safety, tolerability, and preliminary efficacy of ZSNeo-DC1.1, a personalized dendritic cell injection, in subjects with recurrent or progressive WHO grade III-IV gliomas post-standard treatment. The subjects are adult GBM patients who have undergone surgical resection for recurrence. After the completion of reoperation, subjects will receive autologous DC vaccine treatments as scheduled. The autologous genetic-modification-free DC cells will be loaded with multiple tumor neoantigen peptides and administered (i.h) to subjects. After 3 injections, the investigator will review subject's tolerance and compliance. The DLT observation period spans from the initial injection to 21 days after the third injection, aligning with the activation of anti-tumor immune response.

About 15 subjects will be enrolled. The study utilizes a fixed dose of 1×10^7 cells per injection and employs two immunization schedules A or B.

The trial is conducted in two stages:

Dose Confirmation Stage:

Enrollment of six subjects with recurrent or progressive gliomas following standard treatment. Each subject receives six subcutaneous injections of ZSNeo-DC1.1. Utilization of a standard "3+3" design for fixed dose confirmation and exploration of immunization schedules A and B.

Dose Expansion Stage:

Enrollment of at least six subjects with recurrent or progressive gliomas post-standard treatment. Administration of six subcutaneous injections of ZSNeo-DC1.1 to each subject, further investigating the safety and preliminary efficacy of ZSNeo-DC1.1 injection.

연구 개요

연구 유형

중재적

등록 (추정된)

12

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100071
        • Beijing Tiantan Hospital, Capital Medical University

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Participants must meet all the following criteria to be eligible:

    1. Age from 18 to 75 years (including 18 and 75 years old).

    2. Subjects with histologically or cytologically confirmed WHO grade III-IV gliomas experiencing recurrence or progression after standard treatment.

    3. Bridging therapy is allowed during the preparatory period after sample collection, with discontinuation at least 7 days or 5 drug half-lives (whichever is longer) before the initial treatment.

    4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2.

    5. Laboratory test results defining satisfactory hematological and organ function:

      Platelets (PLT) ≥ 90 × 10^9/L; Absolute Neutrophil Count (ANC) ≥ 1.5 × 10^9/L; Haemoglobin (HGB) ≥ 90 g/L; Serum Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 2.5× ULN; Total Bilirubin (TBIL) ≤ 2.5 × ULN; Albumin (ALB) ≥ 3 g/dl; Creatinine clearance rate (CrCl) ≥ 45 mL/minute or Serum Creatinine ≤ 1.5 ×ULN; International Normalized Ratio (INR), Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN; Lipase ≤ 1.5 × ULN; Amylase ≤ 1.5 × ULN; Alkaline Phosphatase (ALP) ≤ 2.5 × ULN.

    6. Adequate tumor and blood samples for NGS gene sequencing can be obtained through tumor reduction surgery or biopsy. Peripheral blood mononuclear cell function is normal.

    7. Relief of any acute, clinically significant treatment-related toxicities (excluding alopecia) to ≤ Grade 1 before the first treatment.

    8. Heart function: Stable hemodynamics, LVEF ≥ 50%.

    9. Adequate venous access for PBMC collection, with no contraindications.

    10. Non-surgically sterilized reproductive-age subjects must use contraception during the study and have a negative pregnancy test.

    11. Expected survival period > 3 months.

    12. Voluntary participation, signed informed consent.

    13. Based on health and lab assessments, the investigator sees favorable risk-benefit for the subject in the clinical trial.

    14. Subjects must consistently comply, actively participate in follow-up visits, and undergo regular testing and evaluation at the research center throughout the trial.

Exclusion Criteria:

  • Subjects meeting any of the following criteria are ineligible:

    1. Recent participation in other drug trials, concurrent anti-tumor therapy (excluding allowed bridging therapy) within 4 weeks before initial treatment, had blood transfusions, EPO, G-CSF, or GM-CSF in the 14 days before peripheral blood mononuclear cell collection, or received live virus vaccinations within 28 days before the first treatment.

    2. Subjects who had camptothecin sustained-release agent implantation surgery within 6 months before the initial treatment.

    3. Active autoimmune diseases, prolonged use of immunosuppressive therapy, or known egg allergy.

    4. Positive for HIV or syphilis antibodies, or active hepatitis B or C.

    5. Recent systemic immunosuppressive treatment within 30 days before the initial treatment.

      Note: Short-term, systemic immunosuppressive treatment may be considered in consultation with the investigator and sponsor approval. The washout period and its duration before the initial treatment will be decided in consultation with the sponsor for these patients.

      Allowed: Inhaled glucocorticoids for COPD, salt corticosteroids (e.g., fludrocortisone) for orthostatic hypotension, and low-dose glucocorticoid supplements (≤10 mg/day prednisone or equivalent) for adrenal insufficiency.

    6. Exclusion: Severe vaccine allergy history, use of attenuated live vaccines within 28 days before initial treatment, or anticipated need within 6 months after the last dose of the investigational drug.

    7. Uncontrolled systemic diseases, including cardiovascular diseases, organ failure, diabetes, and poorly controlled hypertension.

    8. Unmanageable mental illness or significant medical history that may increase risks or interfere with results.

    9. Thrombotic events within the first 6 months before initial treatment, unless anticoagulation can be discontinued during the screening period.

    10. Irreversible electrolyte imbalances.

    11. Severe infection in the first month before initial treatment, poorly controlled infection, or requiring antibiotic treatment within the past week (excluding prophylactic use).

    12. Pregnant or lactating subjects.

    13. Factors judged by the investigator that may necessitate premature study termination, such as non-compliance, other severe diseases requiring concurrent treatment, severe laboratory abnormalities, or family/social factors affecting subject safety or data/sample collection.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 치료 순서 A

Sequence A: For the first 3 cycles, 1 week as a dosing cycle, the next 3 cycles, 3 weeks as a dosing cycle, a total of 6 dosing cycles Sequence B: For the first 3 cycles, 1 week as a dosing cycle, the next 3 cycles, 2 weeks as a dosing cycle, a total of 6 dosing cycles

다른 이름들:
  • DC 백신
실험적: 치료 순서 B

Sequence A: For the first 3 cycles, 1 week as a dosing cycle, the next 3 cycles, 3 weeks as a dosing cycle, a total of 6 dosing cycles Sequence B: For the first 3 cycles, 1 week as a dosing cycle, the next 3 cycles, 2 weeks as a dosing cycle, a total of 6 dosing cycles

다른 이름들:
  • DC 백신

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
AE and SAE
기간: Throughout the whole clinical trial, around 2 years.

Evaluating the incidence rates of Adverse Events and Serious Adverse Events

Throughout the whole clinical trial, around 2 years.
DLT
기간: 2 months

Dose-limiting toxicity.Referencing the results of the exploratory clinical study of ZSNeo-DC1.1 injection, clinical trial outcomes of similar drugs, and the NCI CTCAE 5.0 toxicity assessment criteria to determine DLT. The observation period for DLT is set during the activation of the subject's anti-tumor immune response, from the first day of treatment until 21 days after the third injection.

2 months

2차 결과 측정

결과 측정
측정값 설명
기간
Assessment of ORR (Objective Response Rate)
기간: For Sequence A/B, ORR is measured both on Day57, and after, ORR is measured when every 8 weeks, until the date of disease progression or death, whichever came first, assessed up to 2 years.

According toRANO2.0, to assess the proportion of subjects achieving complete remission (CR) or partial remission (PR).

For Sequence A/B, ORR is measured both on Day57, and after, ORR is measured when every 8 weeks, until the date of disease progression or death, whichever came first, assessed up to 2 years.
Assessment of DCR (Disease Control Rate)
기간: For Sequence A/B, DCR is measured both on Day57, and after, ORR is measured when every 8 weeks, until the date of disease progression or death, whichever came first, assessed up to 2 years.

According to RANO2.0, to assess the proportion of subjects achieving complete remission (CR), partial remission (PR), and stable disease (SD)

For Sequence A/B, DCR is measured both on Day57, and after, ORR is measured when every 8 weeks, until the date of disease progression or death, whichever came first, assessed up to 2 years.
Assessment of CBR (Clinical Benefit Rate)
기간: For Sequence A/B, CBR is measured until the date of disease progression or death, whichever came first, assessed up to 2 years.

According to RANO2.0, to assess the proportion of subjects in each treatment group with the best overall therapeutic effect, defined as the sum of Complete Remission (CR), Partial Remission (PR), and Stable Disease (SD), lasting for at least 6 months.

For Sequence A/B, CBR is measured until the date of disease progression or death, whichever came first, assessed up to 2 years.
Assessment of PFS (Progression Free Survival)
기간: For Sequence A/B, PFS is measured both on Day57, and after, PFS is measured when every 8 weeks), until the date of disease progression or death, whichever came first, assessed up to 2 years.

According to RANO2.0, to assess the PFS of the patients.

For Sequence A/B, PFS is measured both on Day57, and after, PFS is measured when every 8 weeks), until the date of disease progression or death, whichever came first, assessed up to 2 years.
OS (Overall survival)
기간: 2 years

Time from enrollment to the dates of death from any cause or last follow up reported.

2 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 2월 2일

기본 완료 (추정된)

2026년 12월 30일

연구 완료 (추정된)

2026년 12월 31일

연구 등록 날짜

최초 제출

2024년 2월 2일

QC 기준을 충족하는 최초 제출

2024년 2월 2일

처음 게시됨 (실제)

2024년 2월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 28일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 23일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • ZSKY2023-1002

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다